Clinical and immune profiling for cancer of unknown primary site

BACKGROUND: Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP for immunotherapy. METHODS: A total of 164 patients with CUP (favorable subset,...

Descripción completa

Detalles Bibliográficos
Autores principales: Haratani, Koji, Hayashi, Hidetoshi, Takahama, Takayuki, Nakamura, Yasushi, Tomida, Shuta, Yoshida, Takeshi, Chiba, Yasutaka, Sawada, Takahiro, Sakai, Kazuko, Fujita, Yoshihiko, Togashi, Yosuke, Tanizaki, Junko, Kawakami, Hisato, Ito, Akihiko, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743146/
https://www.ncbi.nlm.nih.gov/pubmed/31519206
http://dx.doi.org/10.1186/s40425-019-0720-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743146/
https://www.ncbi.nlm.nih.gov/pubmed/31519206
http://dx.doi.org/10.1186/s40425-019-0720-z

Ejemplares similares